Ray Dalio and Emma Walmsley are not known to have a personal relationship, joint business venture, or formal professional partnership. Their clearest documented connection is that they have appeared at the same high-level international business gatherings, including the 2019 China Development Forum and a March 2025 meeting in Beijing between Chinese President Xi Jinping and more than 40 global business leaders.
There is also a separate financial-market link worth clarifying. Bridgewater Associates, the investment firm Dalio founded, reported owning 504,171 GSK American depositary receipts worth about $26.4 million as of June 30, 2026. That position should not be described as Dalio’s personal investment in Walmsley’s former company because Dalio had sold his remaining ownership stake in Bridgewater in 2025 and was no longer directing the firm’s investment decisions.
What Connects Ray Dalio and Emma Walmsley?
The verified connection between Ray Dalio and Emma Walmsley is primarily through the world of international business and economic policy rather than a direct commercial relationship.
An official list of international delegates for the China Development Forum 2019 named both executives. Walmsley was listed as chief executive of GlaxoSmithKline, while Dalio was listed as chairman of Bridgewater Associates. The forum also included senior leaders from companies such as BlackRock, Blackstone, Pfizer, Unilever, Novartis, BHP and other major global organizations.
They appeared together again in a much more recent setting. Reuters reported that Dalio and Walmsley were both among more than 40 international business leaders who met Chinese President Xi Jinping in Beijing on March 28, 2025, following the China Development Forum. Other participants included executives from Pfizer, AstraZeneca, HSBC, Mercedes-Benz, Saudi Aramco and Samsung.
China’s Ministry of Foreign Affairs and Xinhua confirmed that the March 28 gathering took place at the Great Hall of the People and involved representatives of the international business community. The discussion focused broadly on foreign investment, economic globalization, supply chains and international companies’ role in China’s economy.
These shared appearances establish that Dalio and Walmsley have moved within some of the same global business-policy circles. They do not, by themselves, prove that the two have worked directly with one another.
Ray Dalio and Emma Walmsley at a Glance
| Detail | Ray Dalio | Emma Walmsley |
|---|---|---|
| Main field | Investment management, economics | Pharmaceuticals and consumer business |
| Best known for | Founding Bridgewater Associates | Leading GSK as CEO |
| Major leadership period | Founded Bridgewater in 1975 | GSK CEO from 2017 through 2025 |
| Current status | Bridgewater founder and mentor, no longer an owner | Former GSK CEO, Microsoft independent director |
| Documented shared events | China Development Forum 2019; Beijing business meeting in 2025 | China Development Forum 2019; Beijing business meeting in 2025 |
| Verified direct partnership | None publicly established | None publicly established |
Bridgewater says Dalio founded the company in 1975 and progressively transferred management and investment responsibilities to the next generation. GSK records show Walmsley stepped down as CEO and director at the end of 2025, while Microsoft continues to identify her as an independent board director.
Did Bridgewater Invest in Emma Walmsley’s GSK?
Yes, Bridgewater Associates held GSK securities in 2026, but the distinction between Bridgewater and Ray Dalio personally is important.
Bridgewater’s Form 13F filed with the U.S. Securities and Exchange Commission for the quarter ending June 30, 2026 reported:
| Holding | Reported figure |
|---|---|
| Security | GSK plc sponsored ADR |
| Shares | 504,171 |
| Reported value | $26,428,644 |
| Reporting date | June 30, 2026 |
The same filing also showed Bridgewater holding Haleon ADRs, the consumer-health business separated from GSK in 2022.
This does create an institutional connection between the company Dalio founded and the company Walmsley previously led. It does not establish a personal Dalio-Walmsley transaction.
Dalio’s ownership of Bridgewater had already ended. Reuters reported in July 2025 that Bridgewater bought back the remaining ownership interests held by Dalio-related entities, completing his financial exit from the investment firm he founded.
Bridgewater’s own materials also make clear that the firm’s investment decision-making had shifted away from its founder years earlier. Dalio moved out of the investment decision-making role beginning in 2020, while current investment responsibilities sit with Bridgewater’s institutional leadership and investment structure.
Therefore, describing the June 2026 GSK position as “Ray Dalio investing in Emma Walmsley’s GSK” would be misleading. It was a disclosed Bridgewater Associates portfolio holding.
Who Is Ray Dalio?
Ray Dalio is an American investor best known for founding Bridgewater Associates in 1975. What began in his New York apartment developed into one of the world’s best-known global macro investment firms.
Dalio gradually withdrew from formal leadership. Bridgewater says he stepped down as CEO in 2017, moved away from the CIO role in 2020 and left the chairman position at the end of 2021. The firm’s transfer of control to its next generation of leadership was completed in 2022.
His financial ownership lasted longer. In July 2025, Bridgewater purchased his remaining stake, bringing his ownership relationship with the company to an end. Current Bridgewater operations are led by CEO Nir Bar Dea, with the firm describing Dalio principally through his legacy as its founder and mentor.
Dalio has also become widely associated with writing and commentary on economic cycles, sovereign debt, geopolitics, monetary systems and long-term investing.
Ray Dalio’s Wealth
Forbes estimated Dalio’s real-time net worth at approximately $18.9 billion on September 15, 2026, while noting that such estimates can fluctuate with asset valuations. Forbes identifies hedge funds as the primary source of his fortune.
That figure is an outside estimate rather than an audited statement of his personal assets.
Who Is Emma Walmsley?
Dame Emma Walmsley is a British business executive who became one of the pharmaceutical industry’s most prominent corporate leaders through her tenure at GSK.
Before joining GSK, Walmsley spent approximately 17 years at L’Oréal, working in management and marketing positions in locations including Paris, London, New York and Shanghai. GSK recruited her in 2010 to its consumer-health business.
She was appointed GSK CEO-designate in 2016 and formally became chief executive on April 1, 2017. Her tenure included a major reshaping of GSK’s portfolio, including the separation of its consumer-health operations into Haleon and a stronger corporate focus on vaccines and specialty medicines.
Walmsley stepped down as GSK CEO and from its board on December 31, 2025. Luke Miels became CEO on January 1, 2026. GSK stated that Walmsley would remain an employee through September 30, 2026 to assist with the leadership transition, including work relating to geopolitics and emerging technologies.
As of October 2026, GSK’s current leadership page lists Miels rather than Walmsley as CEO.
Emma Walmsley’s Microsoft Role
Walmsley’s career extends beyond GSK. Microsoft says she joined its board as an independent director in December 2019, and Microsoft’s current leadership materials continue to list her among its board members, now describing her as the former CEO and director of GSK.
Microsoft shareholders also re-elected her to the board in the company’s 2025 director vote.
Emma Walmsley’s Compensation
Reliable information is available about Walmsley’s executive compensation, but not about her total personal net worth.
GSK’s 2025 annual report recorded £15.68 million in total remuneration for Walmsley for 2025, compared with £10.56 million in 2024. Much of the 2025 amount consisted of performance-linked compensation rather than fixed salary.
GSK also disclosed that she would continue receiving salary, benefits and eligible bonus compensation through her employment end date of September 30, 2026 under the agreed departure arrangements.
Unlike Dalio, whose wealth is routinely estimated by major financial publications because of his investment holdings and billionaire status, there is no comparably authoritative public estimate of Walmsley’s personal net worth. Figures circulated by unsourced celebrity-wealth websites should therefore be treated cautiously.
Also Read: Martha Stewart and Emma Walmsley
Did Ray Dalio and Emma Walmsley Work Together?
There is no publicly established joint company, board position, investment partnership or executive role connecting Ray Dalio and Emma Walmsley.
What can be documented is more limited and specific. They have attended the same international business forums, most notably the China Development Forum, and both participated in the March 2025 meeting with President Xi Jinping and other global executives.
Bridgewater also later held GSK shares, but by that point Dalio had exited Bridgewater ownership and GSK had already announced Walmsley’s succession. The investment therefore does not demonstrate a direct relationship between the two individuals.
Why Do Ray Dalio and Emma Walmsley Appear in the Same Business Context?
Their careers occupy different industries, but both reached a level of corporate influence that placed them at major international economic gatherings.
Dalio’s background centers on capital markets, macroeconomics and institutional investing. Walmsley’s background centers on consumer products, pharmaceuticals, vaccines and global corporate management.
China provides one point of overlap. Both have been included in delegations of multinational executives engaging with Chinese policymakers and business leaders. Their inclusion in the 2019 China Development Forum’s international delegate list and the 2025 Beijing meeting reflects their positions within global business circles rather than evidence of a private relationship.
Frequently Asked Questions
Are Ray Dalio and Emma Walmsley business partners?
No verified public record establishes them as business partners. They have attended some of the same international business events, but that is different from operating a company or investment venture together.
Have Ray Dalio and Emma Walmsley met?
Both were participants in the China Development Forum ecosystem and were among the international business leaders reported at the March 28, 2025 meeting with Xi Jinping in Beijing. That confirms attendance at the same gatherings, although publicly available records do not establish the nature or extent of any direct one-to-one interaction between them.
Did Ray Dalio invest in GSK?
It is more accurate to say that Bridgewater Associates invested in GSK. Its June 30, 2026 SEC filing showed 504,171 GSK ADRs valued at roughly $26.4 million. Dalio had sold his remaining Bridgewater ownership stake in 2025, so the disclosed holding should not be attributed to him personally.
Is Emma Walmsley still CEO of GSK?
No. She stepped down as CEO and director on December 31, 2025. Luke Miels became GSK CEO on January 1, 2026, and Walmsley’s remaining employment period ended on September 30, 2026 under the transition arrangements announced by GSK.
What is Emma Walmsley doing now?
Microsoft continues to list Walmsley as an independent director. She joined the Microsoft board in December 2019 and is currently identified by the company as the former CEO and director of GSK.
What is Ray Dalio’s net worth?
Forbes estimated Ray Dalio’s net worth at about $18.9 billion as of September 15, 2026. Net-worth figures are estimates and can change as asset values and financial information change.
Also Read: David Taylor and Emma Walmsley
